Roche to invest CHF450m in new diagnostic manufacturing facility in China
To address Asia Pacific’s growing demand for diagnostic tests
Swiss drugmaker Roche will invest CHF450m (US$460m; £294m) over the next three years to establish a new diagnostic manufacturing facility at the Suzhou Industrial Park, in Suzhou, China.
The company aims to address growing demand for diagnostic tests in China and the Asia Pacific region.
As a new addition to Roche’s global diagnostic production network, the Asia manufacturing facility will produce immunochemistry and clinical chemistry tests, which are crucial to clinical laboratory testing.
The facility will focus on packaging operations in the first phase and will be fully operational by 2018, Roche said.
The company plans to build a workforce of more than 600 people at the site over the next several years.
The new site in China will be Roche's eighth worldwide and its first in the Asia Pacific region.
